Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy
Brain · 19.04.2023 · 146 (4) · 1328-1341
DOI: 10.1093/brain/awac421 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Brain, online erschienen am 09.11.2022. Verfasst von Nancy J Newman und 20 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Ophthalmology, Neurology and Neurological Surgery, Emory University School of Medicine, Atlanta, GA, USA. Hauptthemen laut MEDLINE: Optic Atrophy, Hereditary, Leber. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medical Research Council, NINDS NIH HHS, NEI NIH HHS.
Abstract (Originalsprache)
Leber hereditary optic neuropathy (LHON) is an important example of mitochondrial blindness with the m.11778G>A mutation in the MT-ND4 gene being the most common disease-causing mtDNA variant worldwide. The REFLECT phase 3 pivotal study is a randomized, double-masked, placebo-controlled trial investigating the efficacy and safety of bilateral intravitreal injection of lenadogene nolparvovec in patients with a confirmed m.11778G>A mutation, using a recombinant adeno-associated virus vector 2, serotype 2 (rAAV2/2-ND4). The first-affected eye received gene therapy; the fellow (affected/not-yet-affected) eye was randomly injected with gene therapy or placebo. The primary end point was the difference in change from baseline of best-corrected visual acuity (BCVA) in second-affected/not-yet-affected eyes treated with lenadogene nolparvovec versus placebo at 1.5 years post-treatment, expressed in logarithm of the minimal angle of resolution (LogMAR). Forty-eight patients were treated bilaterally and 50 unilaterally. At 1.5 years, the change from baseline in BCVA was not statistically different between second-affected/not-yet-affected eyes receiving lenadogene nolparvovec and placebo (primary end point). A statistically significant improvement in BCVA was reported from baseline to 1.5 years in lenadogene nolparvovec-treated eyes: −0.23 LogMAR for the first-affected eyes of bilaterally treated patients (P < 0.01); and −0.15 LogMAR for second-affected/not-yet-affected eyes of bilaterally treated patients and the first-affected eyes of unilaterally treated patients (P < 0.05). The mean improvement in BCVA from nadir to 1.5 years was −0.38 (0.052) LogMAR and −0.33 (0.052) LogMAR in first-affected and second-affected/not-yet-affected eyes treated with lenadogene nolparvovec, respectively (bilateral treatment group). A mean improvement of −0.33 (0.051) LogMAR and −0.26 (0.051) LogMAR was observed in first-affected lenadogene nolparvovec-treated eyes and second-affected/not-yet-affected placebo-treated eyes, respectively (unilateral treatment group). The proportion of patients with one or both eyes on-chart at 1.5 years was 85.4% and 72.0% for bilaterally and unilaterally treated patients, respectively. The gene therapy was well tolerated, with no systemic issues. Intraocular inflammation, which was mostly mild and well controlled with topical corticosteroids, occurred in 70.7% of lenadogene nolparvovec-treated eyes versus 10.2% of placebo-treated eyes. Among eyes treated with lenadogene nolparvovec, there was no difference in the incidence of intraocular inflammation between bilaterally and unilaterally treated patients. Overall, the REFLECT trial demonstrated an improvement of BCVA in LHON eyes carrying the m.11778G>A mtDNA mutation treated with lenadogene nolparvovec or placebo to a degree not reported in natural history studies and supports an improved benefit/risk profile for bilateral injections of lenadogene nolparvovec relative to unilateral injections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Ophthalmology, Neurology and Neurological Surgery, Emory University School of Medicine, Atlanta, GA, USA.
- Cambridge Centre for Brain Repair and MRC Mitochondrial Biology Unit, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
- Cambridge Eye Unit, Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, UK.
- Moorfields Eye Hospital, London, UK.
- UCL Institute of Ophthalmology, University College London, London, UK.
- Sue Anschutz-Rodgers University of Colorado Eye Center, University of Colorado School of Medicine, Aurora, CO, USA.
ORCID-Profile: Nancy J Newman, Patrick Yu-Wai-Man
Förderung
- Medical Research Council
- NINDS NIH HHS
- NEI NIH HHS
- GenSight Biologics
Zitieren
APA
Newman, N. J., Yu-Wai-Man, P., Subramanian, P. S., Moster, M. L., Wang, A. G., Donahue, S. P., Leroy, B. P., Carelli, V., Biousse, V., Vignal-Clermont, C., Sergott, R. C., Sadun, A. A., Rebolleda Fernández, G., Chwalisz, B. K., Banik, R., Bazin, F., Roux, M., Cox, E. D., Taiel, M., …, & LHON REFLECT Study Group (2023). Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy. Brain, 146(4), 1328-1341. https://doi.org/10.1093/brain/awac421
Vancouver
Newman NJ, Yu-Wai-Man P, Subramanian PS, Moster ML, Wang AG, Donahue SP, et al. Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy. Brain. 2023;146(4):1328-1341. doi:10.1093/brain/awac421
BibTeX
@article{Newman2023,
author = {Newman, Nancy J and Yu-Wai-Man, Patrick and Subramanian, Prem S and Moster, Mark L and Wang, An-Guor and Donahue, Sean P and Leroy, Bart P and Carelli, Valerio and Biousse, Valerie and Vignal-Clermont, Catherine and Sergott, Robert C and Sadun, Alfredo A and Rebolleda Fernández, Gema and Chwalisz, Bart K and Banik, Rudrani and Bazin, Fabienne and Roux, Michel and Cox, Eric D and Taiel, Magali and Sahel, José-Alain and LHON REFLECT Study Group, LHON REFLECT Study Group},
title = {Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy},
journal = {Brain},
year = {2023},
volume = {146},
number = {4},
pages = {1328--1341},
doi = {10.1093/brain/awac421}
}
EUVIMED